Working... Menu
Trial record 44 of 57 for:    Romidepsin | Phase 2

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02393794
Recruitment Status : Recruiting
First Posted : March 19, 2015
Last Update Posted : October 11, 2018
Celgene Corporation
Bristol-Myers Squibb
Information provided by (Responsible Party):
Priyanka Sharma, University of Kansas Medical Center

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 2019
  Estimated Study Completion Date : July 2020